Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial

Kouchaki, Ebrahim; Tamtaji, Omid Reza; Salami, Mahmoud; Bahmani, Fereshteh; Kakhaki, Reza Daneshvar; Akbari, Elmira; Tajabadi‐Ebrahimi, Maryam; Jafari, Parvaneh; Asemi, Zatollah

doi:10.1016/j.clnu.2016.08.015

Cited by 249 publications

(183 citation statements)

References 26 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…She was taking probiotic supplements at the time of sample collection. Probiotic supplements have been demonstrated their protective roles in anti-inflammation and restoring microbiome in various human diseases, including autoimmune diseases (de Oliveira et al 2017) and multiple sclerosis (Kouchaki et al 2017). However, it is unknown whether using probiotics in this ALS patient contributes to the current F/B ratio.…”

Section: Conclusion/discussionmentioning

confidence: 99%

See 1 more Smart Citation

Gut inflammation and dysbiosis in human motor neuron disease

Rowin¹,

et al. 2017

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a systemic disorder that involves dysfunction of multiple organs. Growing evidence has shown that neurodegenerative disorders with gut dysbiosis affect the central nervous system via pro‐inflammatory mediators thus impacting gut‐brain communications. We have demonstrated dysbiosis and increased intestinal permeability in the SOD1G93A ALS mouse model. In this study, we comprehensively examined the human gut microbiome in stool samples and evaluated infection and markers of intestinal inflammation in five patients with ALS and motor neuron disorders. Five patients we studied all had alteration in their gut microbiome characterized by a low diversity of the microbiome, compared to healthy cohorts with relatively intact abundance. Firmicutes and Bacteroidetes are the two major members of bacteria at the phylum level. Low Ruminococcus spp. occurred in three patients with low Firmicutes/Bacteroidetes (F/B) ratio. A majority of patients had signs of intestinal inflammation. This is the first comprehensive examination of inflammatory markers in the stool of ALS patients. Studies in gut health and microbiome related to the onset and progression of ALS may reveal novel therapeutic targets for disease modulation.

show abstract

Section: Conclusion/discussionmentioning

confidence: 99%

“…) and multiple sclerosis (Kouchaki et al. ). However, it is unknown whether using probiotics in this ALS patient contributes to the current F/B ratio.…”

Section: Conclusion/discussionmentioning

confidence: 99%

Gut inflammation and dysbiosis in human motor neuron disease

Rowin¹,

et al. 2017

View full text Add to dashboard Cite

show abstract

“…4 Furthermore, a recent study reported that supplementation of MS patients with a cocktail of three Lactobacillus species and one Bifidobacterium species was associated with improved Expanded Disability Status Scale (EDSS) score as well as decreased depression and stress. 36 Others studies conducted in the EAE mouse model have demonstrated that administration of a cocktail of Lactobacillus species and/or Bifidobacterium species either before or after EAE induction ameliorate EAE. 37,38 Hence, these studies suggest that increased in the relative abundance of Lactobacillus and Bifidobacterium taxa following LBS supplementation could be beneficial to MS patients.…”

Section: Administration Of Probiotic Lbs Is Associated With Changes Imentioning

confidence: 99%

A probiotic modulates the microbiome and immunity in multiple sclerosis

Tankou

Regev

Healy

et al. 2018

Annals of Neurology

194

116

View full text Add to dashboard Cite

Objective Effect of a probiotic on the gut microbiome and peripheral immune function in healthy controls and relapsing-remitting multiple sclerosis (RRMS) patients. Methods MS patients (N=9) and controls (N=13) were orally administered a probiotic containing Lactobacillus, Bifidobacterium and Streptococcus twice daily for two months. Blood and stool specimens were collected at baseline, after completion of the 2-month treatment, and 3 months after discontinuation of therapy. Frozen peripheral blood mononuclear cells (PBMCs) were used for immune cell profiling. Stool samples were used for 16S rRNA profiling and metabolomics. Results Probiotic administration increased the abundance of several taxa known to be depleted in MS such as Lactobacillus. We found that probiotic use decreased the abundance of taxa previously associated with dysbiosis in MS including Akkermansia and Blautia. Predictive metagenomic analysis revealed a decrease in the abundance of several KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathways associated with altered gut microbiota function in MS patients such as methane metabolism following probiotic supplementation. At the immune level, probiotic administration induced an anti-inflammatory peripheral immune response characterized by decreased frequency of inflammatory monocytes, decreased mean fluorescence intensity (MFI) of CD80 on classical monocytes as well as decreased HLA-DR MFI on dendritic cells. Probiotic administration was also associated with decreased expression of MS risk allele HLA-DQA1 in controls. Probiotic induced increased in the abundance of Lactobacillus and Bifidobacterium were associated with decreased expression of MS risk allele HLA.DPB1 in controls. Interpretation Our results suggest that probiotic could have a synergistic effect with current MS therapies.

show abstract

“…Interestingly, it was recently reported that supplementation of a mixture of Lactobacillus and bifidobacteria in 60 MS patients improved the expanded disability status scale, inflammatory factors, and markers of insulin resistance …”

Section: Microbiota and Probiotics In Autoimmune Diseasesmentioning

confidence: 99%

Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?

Rinaldi

Consonni

Guidesi³

et al. 2018

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Gut microorganisms (microbiota) live in symbiosis with the host and influence human nutrition, metabolism, physiology, and immune development and function. The microbiota prevents pathogen infection to the host, and in turn the host provides a niche for survival. The alteration of gut bacteria composition (dysbiosis) could contribute to the development of immune-mediated diseases by influencing the immune system activation and driving the pro- and anti-inflammatory responses in order to promote or counteract immune reactions. Probiotics are nonpathogenic microorganisms able to interact with the gut microbiota and provide health benefits; their use has recently been exploited to dampen immunological response in several experimental models of autoimmune diseases. Here, we focus on the relationships among commensal bacteria, probiotics, and the gut, describing the main interactions occurring with the immune system and recent data supporting the clinical efficacy of probiotic administration in rheumatoid arthritis, multiple sclerosis, and myasthenia gravis (MG) animal models. The encouraging results suggest that selected strains of probiotics should be evaluated in clinical trials as adjuvant therapy to restore the disrupted tolerance in myasthenia gravis.

show abstract

Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial

Cited by 249 publications

References 26 publications

Gut inflammation and dysbiosis in human motor neuron disease

Gut inflammation and dysbiosis in human motor neuron disease

A probiotic modulates the microbiome and immunity in multiple sclerosis

Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?

Contact Info

Product

Resources

About